Simulations Plus (NASDAQ:SLP) Hits New 12-Month Low at $31.72

Simulations Plus, Inc. (NASDAQ:SLP)’s stock price reached a new 52-week low on Wednesday . The company traded as low as $31.72 and last traded at $31.85, with a volume of 2090 shares changing hands. The stock had previously closed at $31.89.

Wall Street Analyst Weigh In

SLP has been the subject of several recent analyst reports. Craig Hallum restated a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a research report on Wednesday, July 3rd. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Thursday, September 12th. Oppenheimer upped their price objective on Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 13th. JMP Securities initiated coverage on Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. Finally, KeyCorp initiated coverage on Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Simulations Plus presently has an average rating of “Moderate Buy” and an average price target of $56.00.

Simulations Plus Stock Performance

The business has a fifty day simple moving average of $37.36 and a 200-day simple moving average of $42.83. The firm has a market cap of $637.25 million, a price-to-earnings ratio of 66.44 and a beta of 0.70.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.04. The business had revenue of $18.54 million for the quarter, compared to analyst estimates of $17.92 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The company’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 earnings per share. On average, equities analysts anticipate that Simulations Plus, Inc. will post 0.51 earnings per share for the current year.

Simulations Plus Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 5th. Investors of record on Monday, July 29th were given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend was Monday, July 29th. Simulations Plus’s payout ratio is 50.00%.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Daniel L. Weiner sold 750 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the sale, the director now directly owns 7,009 shares of the company’s stock, valued at $345,683.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Simulations Plus news, Director Daniel L. Weiner sold 750 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the sale, the director now directly owns 7,009 shares of the company’s stock, valued at $345,683.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the director now owns 3,501,592 shares of the company’s stock, valued at $123,186,006.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,750 shares of company stock valued at $2,467,390. 20.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its position in shares of Simulations Plus by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after purchasing an additional 456 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new stake in Simulations Plus during the second quarter valued at $811,000. Public Sector Pension Investment Board boosted its stake in Simulations Plus by 6.4% during the second quarter. Public Sector Pension Investment Board now owns 35,227 shares of the technology company’s stock valued at $1,713,000 after buying an additional 2,122 shares during the period. Dimensional Fund Advisors LP boosted its stake in Simulations Plus by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after buying an additional 37,992 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in Simulations Plus by 1.5% during the second quarter. Envestnet Asset Management Inc. now owns 54,813 shares of the technology company’s stock valued at $2,665,000 after buying an additional 784 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.